Printer Friendly

ZONAGEN, INC. NAMES DR. ROBERT A. VUKOVICH TO BOARD OF DIRECTORS; DR. VUKOVICH IS FOUNDER, CEO AND CHAIRMAN OF ROBERTS PHARMACEUTICAL

 THE WOODLANDS, Texas, April 20 /PRNewswire/ -- Zonagen, Inc. (NASDAQ: ZONA) (Pacific Stock Exchange: ZNG) today announced that Dr. Robert A. Vukovich has been named to the company's board of directors. Vukovich has nearly 30 years of experience directing the drug development operations for major pharmaceutical and healthcare companies including Revlon Health Care, the Squibb Institute and Warner-Lambert. He has been responsible for the development and commercialization of over 40 new drugs during his career.
 In 1983, he founded Roberts Pharmaceutical Corporation, and has served as chief executive officer and chairman of the board since that time. Roberts has established a number of strategic alliances with multinational corporations such as DuPont, Bayer, Upjohn and Yamanouchi. Since inception, Roberts has developed a pipeline of six late-stage products submitted as New Drug Applications or the foreign equivalence, commenced operation in seven countries and, in 1992 registered sales of $3.3 million.
 "Bob Vukovich has tremendous expertise in forming strategic business alliances and steering products through the FDA approval process, as demonstrated by the emergence of Roberts Pharmaceutical as a leading international pharmaceutical company," said Joseph S. Podolski, Zonagen's president. "We are delighted that he will be joining Zonagen's board, and we look forward to his counsel in helping to direct the course of Zonagen's growth."
 Prior to founding Roberts, Vukovich served as the director of Revlon Health Care Group's Division of Developmental Therapeutics. Between 1971 and 1979 he held positions with The Squibb Institute for Medical Research, most recently as director of Clinical Pharmacology. He began his career as a clinical research scientist at Warner-Lambert Research, and held subsequent positions at the Waldemar Medical Research Foundation and USV Pharmaceutical Corporation.
 Vukovich received a Ph.D. in Pharmacology from Jefferson Medical College in 1969, and a bachelor of science degree in biology from Allegheny College in 1965. He was a finalist in Inc. magazine's Entrepreneur of the Year selection in 1990 and 1991, and received the award in 1992 in the New Jersey Life Sciences/Biology category. In 1989, Roberts Pharmaceutical was selected as New Jersey's fastest growing private company.
 Zonagen is engaged in the development of pharmaceutical products for the female reproductive system including human contraceptives and a series of products designed to sterilize female animals. The company's first products will originate from its proprietary and patented technology relating to the zona pellucida, the protein-rich shell surrounding a mammalian egg. Although the company's long-term strategy is to develop human contraceptives and related products, the company's initial efforts will emphasize the development of genetically engineered vaccines that could replace surgical spaying for the sterilization of animals.
 -0- 4/20/93
 /CONTACT: Joseph S. Podolski, president of Zonagen, Inc., 713-367-5892; or Marcia Kean, executive vice president or Chris Taylor, both of Feinstein Partners Inc., 617-577-8110 for Zonagen, Inc./
 (ZONA)


CO: Zonagen, Inc. ST: Texas, New Jersey IN: MTC SU: PER

CH -- NE002 -- 7842 04/20/93 09:24 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1993
Words:484
Previous Article:WEBSTER FINANCIAL CORPORATION REPORTS EARNINGS INCREASE
Next Article:GTECH TOPS $500 MILLION FOR FISCAL YEAR; COMPANY REPORTS FOURTH-QUARTER AND YEAR-END OPERATING RESULTS
Topics:


Related Articles
ROBERTS PHARMACEUTICALS CEO NAMED ENTREPRENEUR OF THE YEAR
ROBERTS PHARMACEUTICAL CORPORATION ELECTS NEW DIRECTOR
Roberts Pharmaceutical Corporation Announces Decision of Its Founder to Retire.
InfaCare Names Paul J. Marangos CEO and Director; New Company Will Focus on Neonatal and Pediatric Therapeutics.
InfaCare Names Horace Hertz CFO; New Company Will Focus on Neonatal and Pediatric Therapeutics.
InfaCare Names John R. Post COO; Company Focus on Neonatal and Pediatric Therapeutics.
InfaCare Names Ronald Goldfuss CFO.
WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical...
WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters